Izabela Sabala brings a strong background in protein biochemistry, along with deep insight and practical strategies to her work. Her research is focused on engineering of a new class of antimicrobials—enzybiotics. These are enzymes with exceptional antimicrobial activity, currently being developed as a promising alternative to traditional antibiotics in the fight against the growing crisis of antimicrobial resistance.
This presentation explores the innovative approach of engineering enzymes to develop enzybiotics—enzyme-based antibacterial agents—as a promising alternative to traditional antibiotics. It highlights how specific modifications, such as domain swapping, mutagenesis, and fusion with targeting peptides, can enhance enzyme stability, specificity, and bactericidal efficiency. The talk also covers recent successes in combating multidrug-resistant pathogens and discusses future directions for optimizing delivery, broadening the antibacterial spectrum, and overcoming resistance mechanisms.